Q-omics provides the consensus-scored PTTG4P profile across patient tissues and cancer cell-line models. PTTG4P expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, PTTG4P is differentially expressed in 8, with the highest sampling consensus in THCA. Additionally, PTTG4P RNA expression shows 15,153 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight HNSC, THCA, and THYM as cancer lineages where PTTG4P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PTTG4P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PTTG4P survival associations across molecular data types. PTTG4P RNA expression shows survival associations in the most cancer types (18). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PTTG4P RNA expression–survival associations across cancer types. High PTTG4P expression shows unfavorable associations in KIRC, but favorable associations in HNSC, ESCA, READ, BRCA and KIRP. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for PTTG4P RNA expression.
This table summarizes PTTG4P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for PTTG4P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PTTG4P shows lower tumor expression in THCA, BRCA and LUSC and higher tumor expression in KICH, LUAD and HNSC. The THCA box plot shows higher PTTG4P RNA expression in normal versus tumor tissue (log2 FC = −0.215, t-test p = .010).
This table shows molecular features associated with PTTG4P in patient tissues and cancer cell lines. In patient samples, PTTG4P shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
